title: Oral and maxillofacial myiasis: a case series and literature review.
abstract: OBJECTIVE
  The aim of this study was to describe a series of 10 cases of oral-maxillofacial myiasis, discussing its main features, demographic distribution, and treatment aspects.
  
  
  METHODS
  A retrospective study was carried out involving male and female patients of any age with oral-maxillofacial myiasis. The sample was determined by spontaneous demand at the emergency ward of a hospital between January 2005 and January 2011 (6 years). After treatment of each case, data were gathered on the presence of associated systemic disorders, time elapsed since onset of the disease, and treatment established. A review of the literature on this topic was also carried out.
  
  
  RESULTS
  The sample was made up of 10 patients, all treated with surgical debridement whether or not associated with the use of oral ivermectin. Mean time elapsed since the onset of the disease ranged from 4 to 36 months. The middle third of the face was the most frequently affected region (7 cases). Oral-maxillofacial myiasis predominantly affected the male gender (70%).
  
  
  CONCLUSIONS
  Oral-maxillofacial myiasis affects individuals with poor hygiene and neurologic and/or psychologic alterations. It occurs predominantly in countries near the tropics. The treatment of choice is surgical debridement.
authors.affiliation: Oral and Maxillofacial Surgeon, University of São Paulo, São Paulo, Brazil. antunesctbmf@yahoo.com.br
authors.forename: Antonio Azoubel
authors.initials: AA
authors.lastname: Antunes
authors.forename: Thiago de Santana
authors.initials: Tde S
authors.lastname: Santos
authors.forename: Rafael Linard
authors.initials: RL
authors.lastname: Avelar
authors.forename: Evandro Carneiro
authors.initials: EC
authors.lastname: Martins Neto
authors.forename: Bruno
authors.initials: B
authors.lastname: Macedo Neres
authors.forename: José Rodrigues
authors.initials: JR
authors.lastname: Laureano Filho
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000700:Analgesics / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000977:Antiparasitic Agents / Q000627:therapeutic use; D002908:Chronic Disease; D003131:Combined Modality Therapy; D003646:Debridement; D005148:Facial Dermatoses / Q000469:parasitology* / Q000601:surgery; D005260:Female; D006801:Humans; D007559:Ivermectin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009059:Mouth Diseases / Q000469:parasitology* / Q000601:surgery; D009198:Myiasis / Q000175:diagnosis* / Q000601:surgery; D009894:Opportunistic Infections / Q000469:parasitology; D012189:Retrospective Studies
chemical_list: D000700:Analgesics; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000977:Antiparasitic Agents; D007559:Ivermectin